Malawi-Liverpool-Wellcome Trust Clinical Research Programme


The Malawi Liverpool Wellcome Trust (MLW) is a partnership between LSTM, University of Liverpool, Kamuzu University of Health Sciences (KUHeS), and The Wellcome Trust. With over 25 years’ experience, MLW celebrates success in translational research, regional and global health priorities, malaria, tuberculosis, HIV, pneumonia treatments, maternal/ child health, and vaccine policy.A recent MLW trial of typhoid conjugate vaccine (TCV), the first in Africa, showed efficacy of over 80%. This safe vaccine works well at preventing typhoid fever in African children, giving a highly immunogenic response in all age groups. MLW and the Ministry of Health lobbied the Global Alliance for Vaccines and Immunizations (GAVI) to fund TCV, and it is now a routine vaccination.

Through their AMBITION trial, MLW found a single high-dose of liposomal amphotericin B is a simpler, more cost-effective treatment for cryptococcal meningitis (CM) than the usual Amphotericin-B. The trial results changed treatment guidelines for cryptococcal meningitis in Malawi and worldwide. MLW also provided COVID-19 diagnostics and in-country sequencing capacity, throughout the pandemic. An oxygen plant for treatment of COVID-19 and respiratory patients is now available at Queen Elizabeth Central Hospital, supported by a grant from Wellcome.